Cargando…

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitaichi, Yuji, Inoue, Takeshi, Mitsui, Nobuyuki, Nakagawa, Shin, Kameyama, Rie, Hayashishita, Yoshiyuki, Shiga, Tohru, Kusumi, Ichiro, Koyama, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804584/
https://www.ncbi.nlm.nih.gov/pubmed/24204150
http://dx.doi.org/10.2147/NDT.S49261
Descripción
Sumario:We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerable, and electroconvulsive therapy had only a temporary effect. After 20 weeks of treatment with selegiline (10 mg/day), the patient’s score on the 17-item Hamilton Depression Rating Scale (HDRS) had decreased from 19 to 4 points. [(18)F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased glucose metabolism in the bilateral basal ganglia after initiating selegiline treatment; blood dopamine levels were also increased after selegiline treatment. These results raise the possibility that selegiline enhances dopamin-ergic neural transmission in treatment-resistant depression, thus leading to an improvement in depressive symptoms.